Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
AstraZeneca
Medtronic
McKinsey

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,419,307

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,419,307 protect, and when does it expire?

Patent 8,419,307 protects AXIRON and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 8,419,307
Title:Spreading implement
Abstract: Described are methods comprising applying a liquid pharmaceutical testosterone composition with an implement comprising a support and a receptacle mounted on the support and defining a reservoir space with an open top to receive the liquid, wherein the receptacle includes a flexible membrane integrally forming a base and a wall, the wall being substantially transverse to the base and having a working surface to spread the liquid over the treatment surface, wherein the base has a continuous surface such that liquid cannot pass through the base, wherein the wall includes an inner portion which extends from the base to an upper end and an outer skirt portion, wherein the inner portion and skirt portion form a double-wall structure, and wherein at least the wall is resiliently deformable so the working surface maintains contact with the treatment surface when spreading the liquid.
Inventor(s): Bayly; Peter (Victoria, AU), Bayly; Mark Simon (Victoria, AU), Ahlstrom; Magnus (Victoria, AU), Watkinson; Adam Charles (Victoria, AU)
Assignee: Acrux DDS Pty Ltd. (West Melbourne, Victoria, AU)
Application Number:13/464,556
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,419,307
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 8,419,307

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No   Start Trial   Start Trial A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,419,307

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007343579   Start Trial
Brazil PI0720945   Start Trial
Canada 2674661   Start Trial
China 101636194   Start Trial
Eurasian Patent Organization 015473   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Merck
McKinsey
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.